NEW APPROACHES TO TREATMENT OF GASTROINTESTINAL CANCER

在未来五年的项目中，我们将继续 作出强有力的努力，使在一个协调的单位， 马约临床研究学科和相关实验室 以改善姑息和治疗为目的的诊所 治疗人胃肠癌。 以下 具体领域将被解决：1）治疗结直肠癌 癌2)治疗不常见的胃肠道疾病 癌和3）胃肠癌实验室科学。 我们继续特别强调发展和 区域疾病和外科手术创新方法的试验 以治愈为特定终点的辅助治疗。 原发性 重要的是将直接整合到临床研究中 在癌症方面的复杂实验室工作计划 药理学、细胞遗传学和免疫学。 我们将继续 利用该计划的特殊优势，其中包括 在胃肠道临床癌症方面的卓越经验 研究;一个专门的临床研究团队，包括所有有关 学科;异常庞大的癌症患者群体 可在马约诊所进行有意义的研究， 及时进行;独特的大量人口 新诊断的胃肠道癌症，允许进行 早期疾病研究;一个非常大的人口， 不太常见的癌症患者;与 我们地区的社区诊所通过北中央癌症 允许连续管理的治疗组， 使用相同数据库的扩展III期试验; 建立了马约癌症中心统计单位， 在我们研究的所有阶段，以确保合理的协议设计， 一致的数据质量，知情和客观的数据分析; 以及大量组织和实验室的现成可用性 基础实验室研究材料。 我们相信这些成分 结合我们既定的生产力和我们记录在案的 在头两年半的时间里， 赠款提供最大的信心，拟议的工作将 符合最高的科学标准，并将进行 无与伦比的质量和成本效益。

Over the next five years of this Program Project we will continue to make strong efforts to bring together in a coordinated unit the clinical research disciplines and related laboratories of the Mayo Clinic for the purpose of improving both palliative and curative treatment of human gastrointestinal cancer. The following specific areas will be addressed: 1) Treatment of colorectal cancer. 2) Treatment of the less common gastrointestinal carcinomas and 3) Gastrointestinal Cancer Laboratory Science. We continue to place special emphasis on the development and testing of innovative approaches to regional disease and surgical adjuvant therapy with cure as a specific end point. Of primary importance will be the integration directly into clinical research programs of sophisticated laboratory endeavors in cancer pharmacology, cytogenetics and immunology. We will continue to utilize the particular strengths of this program which include an unexcelled depth of experience in gastrointestinal clinical cancer research; a devoted clinical research team including all concerned disciplines; the exceptionally large cancer patient population available at the Mayo Clinic permitting meaningful studies to be performed in a timely fashion; the uniquely large population of newly diagnosed gastrointestinal cancer permitting conduct of early disease studies; an extraordinarily large population of patients with less common cancers; strong relationships with community clinics in our region through the North Central Cancer Treatment Group permitting a continuum of management and expanded Phase III trials utilizing the same data base; a well developed Mayo Cancer Center Statistical Unit which is involved in all phases of our studies to insure sound protocol design, consistent data quality, and informed and objective data analysis; and ready availability of large amount of tissue and laboratory materials for basic laboratory study. We believe these ingredients combined with our established productivity and our documented accomplishment during the first two and one-half years of this grant provide maximum confidence that the work proposed will meet highest scientific standards and will be conducted with unexcelled quality and cost effectiveness.